Chi-Med doubles revenue to $46m

Shares in China-focused healthcare group Hutchison China MediTech – known an Chi-Med – climbed over four per cent yesterday after it announced a doubling of revenue to $46m and a 65 per cent rise in operating profit to $9.6m last year. It has deals with Eli Lilly, AstraZeneca, and Nestle Health Science.